Laura Di Leo1, Federico Nalesso2, Francesco Garzotto1,2, Yun Xie1,3, Bo Yang1,4, Grazia Maria Virzì1,2, Alberto Passannante1,5, Raffaele Bonato6, Mariarosa Carta7, Davide Giavarina7, Dario Gregori8, Alessandra Brendolan1,2, Fiorenza Ferrari1, Claudio Ronco1,2. 1. International Renal Research Institute of Vicenza, San Bortolo Hospital, Vicenza, Italy. 2. Department of Nephrology, Dialysis and Transplantation, San Bortolo Hospital, Vicenza, Italy. 3. Department of Nephrology, Xin Hua Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai, China. 4. Department of Nephrology, First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin, China. 5. Department of Anaesthesia and Intensive Care, University of Trieste, Trieste, Italy. 6. Department of Intensive Care, San Bortolo Hospital, Vicenza, Italy. 7. Department of Laboratory Medicine, San Bortolo Hospital, Vicenza, Italy. 8. Biostatistics, Epidemiology and Public Health Unit, Department of Cardiac, Thoracic and Vascular Sciences, University of Padova, Padova, Italy.
Abstract
BACKGROUND: Acute kidney injury (AKI) diagnosis is based on a rise in serum creatinine and/or fall in urine output. It has been shown that there are patients that fulfill AKI definition but do not have AKI, and there are also patients with evidence of renal injury who do not meet any criteria for AKI. Recently the innovative and emerging proteomic technology has enabled the identification of novel biomarkers that allow improved risk stratification. METHODS: Tissue inhibitor of metalloproteinases-2 (TIMP-2), insulin-like growth factor-binding protein 7 (IGFBP7) were measured to a cohort of 719 consecutive patients admitted to Intensive Care Unit (ICU). The primary endpoint was the evaluation of clinical performances of the biomarkers focusing on the probability do develop AKI in the first 7 days. RESULTS: The Kaplan-Meier analysis considering the first 7 days of ICU stay suggested a lower risk of developing AKI (p < 0.0001) for patients with a negative (<0.3; TIMP-2*IGFBP7) test. CONCLUSION: (TIMP-2*IGFBP7) at ICU admission has a good performance in predicting AKI, especially in the first 4 days in ICU.
BACKGROUND:Acute kidney injury (AKI) diagnosis is based on a rise in serum creatinine and/or fall in urine output. It has been shown that there are patients that fulfill AKI definition but do not have AKI, and there are also patients with evidence of renal injury who do not meet any criteria for AKI. Recently the innovative and emerging proteomic technology has enabled the identification of novel biomarkers that allow improved risk stratification. METHODS:Tissue inhibitor of metalloproteinases-2 (TIMP-2), insulin-like growth factor-binding protein 7 (IGFBP7) were measured to a cohort of 719 consecutive patients admitted to Intensive Care Unit (ICU). The primary endpoint was the evaluation of clinical performances of the biomarkers focusing on the probability do develop AKI in the first 7 days. RESULTS: The Kaplan-Meier analysis considering the first 7 days of ICU stay suggested a lower risk of developing AKI (p < 0.0001) for patients with a negative (<0.3; TIMP-2*IGFBP7) test. CONCLUSION: (TIMP-2*IGFBP7) at ICU admission has a good performance in predicting AKI, especially in the first 4 days in ICU.
Authors: David S Gardner; Jennifer C Allen; Deborah Goodson; Daniel Harvey; Andrew Sharman; Henry Skinner; Adam Szafranek; John S Young; Elizabeth H Bailey; Mark A J Devonald Journal: Kidney Int Rep Date: 2022-04-29
Authors: Fiorenza Ferrari; Mariangela Valentina Puci; Ottavia Eleonora Ferraro; Gregorio Romero-González; Faeq Husain-Syed; Lilia Rizo-Topete; Mara Senzolo; Anna Lorenzin; Eva Muraro; Antonio Baracca; Mara Serrano-Soto; Alejandra Molano Triviño; Ana Coutinho Castro; Massimo De Cal; Valentina Corradi; Alessandra Brendolan; Marta Scarpa; Maria Rosa Carta; Davide Giavarina; Raffaele Bonato; Giorgio Antonio Iotti; Claudio Ronco Journal: PLoS One Date: 2019-06-20 Impact factor: 3.240
Authors: Federico Nalesso; Leda Cattarin; Laura Gobbi; Antonio Fragasso; Francesco Garzotto; Lorenzo Arcangelo Calò Journal: Int J Nephrol Renovasc Dis Date: 2020-04-24
Authors: Federico Nalesso; Federica L Stefanelli; Valentina Di Vico; Leda Cattarin; Irene Cirella; Giuseppe Scaparrotta; Francesco Garzotto; Lorenzo A Calò Journal: Biomedicines Date: 2022-08-19
Authors: Karolina Woziwodzka; Jolanta Małyszko; Ewa Koc-Żórawska; Marcin Żórawski; Paulina Dumnicka; Artur Jurczyszyn; Krzysztof Batko; Paulina Mazur; Małgorzata Banaszkiewicz; Marcin Krzanowski; Paulina Gołasa; Jacek A Małyszko; Ryszard Drożdż; Katarzyna Krzanowska Journal: Medicina (Kaunas) Date: 2021-12-10 Impact factor: 2.430